Michael R. Grunwald, MD, FACP

Articles by Michael R. Grunwald, MD, FACP

Clinical Implications of Tisagenlecleucel in B-ALL Treatment: Michael R. Grunwald, MD, FACP

July 18th 2021

The hematologic oncologist at the Levine Cancer Institute discussed the clinical implications of tisagenlecleucel in the treatment of patients with B-cell acute lymphoblastic leukemia.

Dr. Grunwald on the Efficacy of 19-28z CAR T-Cell Therapy in B-ALL

ByMichael R. Grunwald, MD, FACP

April 27th 2021

Michael R. Grunwald, MD, FACP, discusses the efficacy of 19-28z CAR T-cell therapy in B-cell acute lymphoblastic leukemia.

Michael R. Grunwald, MD, FACP

Articles by Michael R. Grunwald, MD, FACP

Clinical Implications of Tisagenlecleucel in B-ALL Treatment: Michael R. Grunwald, MD, FACP

Dr. Grunwald on the Efficacy of 19-28z CAR T-Cell Therapy in B-ALL

Latest Updated Articles

Trending on CGTlive®

AAVantgarde’s Stargardt Gene Therapy AAVB-039 Garners FDA Orphan Drug Designation, Cleared for Trial in UK

Sarepta Therapeutics’ Limb-Girdle Muscular Dystrophy Gene Therapy SRP-9003 Produces “Robust Expression” of β-SG in Phase 3 Trial